Bizarre Patents
Apparatus for Simulating a High Five
A self-righting hand-arm configuration which is adapted to pivot when struck by a user, thereby simulating a "high five."
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8178086 | Activation of HCV specific T cells Methods for activating HCV-specific T cells are described. The methods utilize one or more administrations of HCV protein compositions, followed by one or more administrations of a viral vector comprising a nucleic acid encoding a least one HCV epitope that is prese... | 05/15/2012 |
| 8119146 | Expressing hepatitis B virus surface antigen for vaccine preparation HBsAg is expressed in a Saccharomyces cerevisiae host, carrying a plasmid having a HBsAg coding sequence, wherein the plasmid includes: (1) an upstream promoter from a glyceraldehyde-3-phosphate dehydrogenase gene, for controlling expression of the HBsAg codi... | 02/21/2012 |
| 8092813 | Polychlorinated biphenyls and squalene-containing adjuvants When using squalene in a vaccine adjuvant, there is a possibility of contamination with polychlorinated biphenyls (PCBs). Environmental exposure to PCBs may adversely affect children's immune responses to routine vaccinations. Thus the invention uses squalene with l... | 01/10/2012 |
| 8021834 | Use of microparticles combined with submicron oil-in-water emulsions Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submi... | 09/20/2011 |
| 7829078 | Methods of treating anemia using recombinant adeno-associated virus virions The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., ... | 11/09/2010 |
| 7824688 | Glucan-based vaccines Anti-glucan antibodies have been found to be protective against systemic fungal infection with C. albicans, but the protective efficacy can be inhibited by blocking antibodies. The invention provides an immunogenic composition comprising a glucan and a pharma... | 11/02/2010 |
| 7815623 | Stepped cannula Described herein are cannulas having a stepped exterior. Also described are methods of making and using these cannulas, for example to deliver one or more materials to the central nervous system of an animal. ... | 10/19/2010 |
| 7749518 | Polypeptides from non-typeable Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine... | 07/06/2010 |
| 7638679 | Tolerance and chronic hepatitis C virus This invention provides a model for the induction of immunological tolerance to antigens. The tolerance model of the invention can be used for screening candidate drugs effective in modulating tolerance. The invention also provides the use of such tolerance-modulati... | 12/29/2009 |
| 7439058 | HBV/HCV virus-like particle Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an im... | 10/21/2008 |
| 7393630 | Use of microparticles combined with submicron oil-in-water emulsions Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submi... | 07/01/2008 |
| 7319144 | Polynucleotides encoding a multiple epitope fusion antigen for use in an HCV antigen/antibody combination assay The invention relates to a method of detecting HCV infection in a biological sample, the method comprising providing an immunoassay solid support, comprising an HCV anti-core antibody, an antigen comprising an HCV NS3/4a epitope, and an HCV multiple epitope f... | 01/15/2008 |
| 7285539 | Activation of HCV-specific T cells The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides... | 10/23/2007 |
| 7279169 | Mucosal DTPa vaccines Mucosal DTPa vaccines, especially intranasal vaccines, comprising (a) a diphtheria antigen, a tetanus antigen and an acellular pertussis antigen, and (b) a detoxified mutant of cholera toxin (CT) or E. coli heat labile toxin (LT). Component (b) acts as a muco... | 10/09/2007 |
| 7265089 | KGF polypeptide compositions Compositions comprising keratinocyte growth factor (KGF) polypeptides and methods of using the same are described. The KGF polypeptides of the present invention display enhanced bioactivity relative to full-length KGF163. Accordingly, the KGF polypeptides... | 09/04/2007 |
| 7252958 | Modulation of tetraspanin function Tetraspanins have been found to dimerise. Methods for inhibiting or promoting the dimerisation of tetraspanins are provided, which may involve protein engineering of the tetraspanins themselves, or may rely on other molecules. ... | 08/07/2007 |
| 7252827 | Conserved motif of hepatitis C virus E2/NS1 region Fusion proteins comprising an immunogenic polypeptide are disclosed. The immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SE... | 08/07/2007 |
| 7241879 | Immunoassays for anti-HCV antibodies HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays. ... | 07/10/2007 |
| 7198923 | Method for the preparation of purified HCV RNA by exosome separation The invention relates to a method for the isolation of hepatitis C virus. The method comprises the separation of particles termed exosomes from the blood plasma of an individual infected with hepatitis C virus (HCV) and the extraction or RNA from these exosome parti... | 04/03/2007 |
| 7193042 | Methods for purifying authentic IGF from yeast hosts Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains. ... | 03/20/2007 |
| 7183107 | Enhanced replication of HCV RNA This invention provides methods of generating cells that stably replicate sub-genomic virus replicons. This invention also provides methods of generating cells that have disabled PKR activity and that stably replicate HCV sub-genomic replicons. The invention also pr... | 02/27/2007 |
| 7179457 | Modified nodavirus RNA for gene delivery The invention provides a nodavirus RNA1 molecule modified to include a heterologous insertion which is downstream of its replicase ORF and, preferably, its B2 ORF. The insertion preferably comprises one or more protein-coding regions. The modified RNA1 may be packag... | 02/20/2007 |
| 7169392 | serogroup B glycoconjugates and methods of producing the same The present invention pertains generally to novel Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (Men... | 01/30/2007 |
| 7166426 | HCV assay An HCV antigen/antibody/antigen assay is provided. The assay employs an isolated first antigen from a region of the HCV polyprotein, and an HCV multiple epitope fusion antigen that includes an epitope from the same region of the polyprotein as the first antigen. Bot... | 01/23/2007 |
| 7135185 | Conserved motif of hepatitis C virus E2/NS1 region Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-... | 11/14/2006 |
| 7112330 | Method for producing yeast expressed HPV types 6 and 16 capsid proteins Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLP... | 09/26/2006 |
| 7108967 | Hepatitis C viral antigen immunoassay detection systems Immunoassays for detecting hepatitis C virus protein and immune complexes between hepatitis C virus protein and antibodies in biological samples, methods of screening blood products for hepatitis C virus, and kits employed therefor are provided. ... | 09/19/2006 |
| 7105303 | Antibodies to hepatitis C virus asialoglycoproteins Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more simi... | 09/12/2006 |
| 7097987 | Hepatitis C receptor protein CD81 The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes. ... | 08/29/2006 |
| 7098303 | Conserved motif of hepatitis C virus E2/NS1 region Immunogenic polypeptides comprising hepatitis C virus (HCV) immunogens are described. The HCV immunogen comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-P he-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SE... | 08/29/2006 |
| 7084119 | Truncated keratinocyte growth factor (KGF) having increased biological activity The present invention relates to a keratinocyte growth factor fragment, KGFdes1-23, or an analog thereof that is composed of a portion of an amino acid sequence of mature, full length keratinocyte growth factor, KGF163. The fragment exhibits at... | 08/01/2006 |
| 7071313 | Methods of purifying authentic IGF from yeast hosts Methods for purifying authentic, properly folded IGF polypeptides from yeast transformants are disclosed. The methods include a refolding step and provide for high yields of authentic IGF from a variety of yeast strains. ... | 07/04/2006 |
| 7067485 | IGF-I composition and its use A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to... | 06/27/2006 |
| 7063949 | Methods for isolating molecular mimetics of unique serogroup B epitopes Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The ant... | 06/20/2006 |
| 7056658 | Multiple epitope fusion protein Multiple epitope fusion proteins and immunoassays using the same are disclosed. The multiple epitope fusion proteins are encompassed by the general structural formula (A)x−(B)y−C2 which represents a linear amino acid sequence, wh... | 06/06/2006 |
| 7048924 | Combination antiviral and interleukin-2 therapy for HIV infection Methods for promoting immunologic control of human immunodeficiency virus (HIV) in an HIV-infected subject are provided. The methods comprise administering to the subject highly active antiretroviral therapy (HAART) for at least one cycle of an intermittent dosing r... | 05/23/2006 |
| 7033805 | HCV NS3 protein fragments having helicase activity and improved solubility The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amin... | 04/25/2006 |
| 7026130 | Binding protein A 24kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), and functionally equivalent variants or fragments of the 24kd protein, are disclosed. Processes for production and purification of the 24kd protein, and functionally equivalent var... | 04/11/2006 |
| 6986892 | Immunogenic Hepatitis C virus non-structural polypeptides Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupt the catalytic domain of NS3. Polynucleotides encoding these ... | 01/17/2006 |
| 6942965 | Hepatitis A virus nucleotide sequences, recombinant proteins and uses thereof Hepatitis A virus primers and probes derived from the capsid proteins and junction between the capsid precursor P1 and 2A of the HAV genome are disclosed. Also disclosed are nucleic acid-based assays using the primers and probes, antigen detection of HAV, and immuno... | 09/13/2005 |
